123 related articles for article (PubMed ID: 28093282)
1. IL-1β induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
Mendoza-Rodríguez M; Arévalo Romero H; Fuentes-Pananá EM; Ayala-Sumuano JT; Meza I
Cancer Lett; 2017 Apr; 390():39-44. PubMed ID: 28093282
[TBL] [Abstract][Full Text] [Related]
2. IL-1β Inflammatory Cytokine-Induced
Mendoza-Rodríguez MG; Ayala-Sumuano JT; García-Morales L; Zamudio-Meza H; Pérez-Yepez EA; Meza I
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641908
[TBL] [Abstract][Full Text] [Related]
3. CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1β.
García-Morales L; Castillo AM; Tapia Ramírez J; Zamudio-Meza H; Domínguez-Robles MDC; Meza I
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244518
[TBL] [Abstract][Full Text] [Related]
4. IL-1β induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells.
Jiménez-Garduño AM; Mendoza-Rodríguez MG; Urrutia-Cabrera D; Domínguez-Robles MC; Pérez-Yépez EA; Ayala-Sumuano JT; Meza I
Biochem Biophys Res Commun; 2017 Aug; 490(3):780-785. PubMed ID: 28645612
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.
Katanov C; Lerrer S; Liubomirski Y; Leider-Trejo L; Meshel T; Bar J; Feniger-Barish R; Kamer I; Soria-Artzi G; Kahani H; Banerjee D; Ben-Baruch A
Stem Cell Res Ther; 2015 May; 6(1):87. PubMed ID: 25928089
[TBL] [Abstract][Full Text] [Related]
6. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Wang D; Berglund A; Kenchappa RS; Forsyth PA; Mulé JJ; Etame AB
Sci Rep; 2016 Feb; 6():21710. PubMed ID: 26888114
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.
Kim B; Stephen SL; Hanby AM; Horgan K; Perry SL; Richardson J; Roundhill EA; Valleley EM; Verghese ET; Williams BJ; Thorne JL; Hughes TA
BMC Cancer; 2015 Sep; 15():634. PubMed ID: 26362310
[TBL] [Abstract][Full Text] [Related]
8. SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells.
Gan H; Liu H; Zhang H; Li Y; Xu X; Xu X; Xu J
Tumour Biol; 2016 Jul; 37(7):9943-50. PubMed ID: 26815504
[TBL] [Abstract][Full Text] [Related]
9. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
10. A novel β-catenin signaling pathway activated by IL-1β leads to the onset of epithelial-mesenchymal transition in breast cancer cells.
Perez-Yepez EA; Ayala-Sumuano JT; Lezama R; Meza I
Cancer Lett; 2014 Nov; 354(1):164-71. PubMed ID: 25135221
[TBL] [Abstract][Full Text] [Related]
11. IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
Oh K; Lee OY; Park Y; Seo MW; Lee DS
BMC Cancer; 2016 Sep; 16(1):724. PubMed ID: 27609180
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
13. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
Zhang D; Putti TC
Exp Cell Res; 2010 Dec; 316(20):3522-31. PubMed ID: 20833165
[TBL] [Abstract][Full Text] [Related]
15. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
[TBL] [Abstract][Full Text] [Related]
16. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
17. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
Chen C; Shen HL; Yang J; Chen QY; Xu WL
J Cancer Res Clin Oncol; 2011 Jan; 137(1):9-17. PubMed ID: 20229271
[TBL] [Abstract][Full Text] [Related]
18. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
19. Specific regulation of PRMT1 expression by PIAS1 and RKIP in BEAS-2B epithelia cells and HFL-1 fibroblasts in lung inflammation.
Liu L; Sun Q; Bao R; Roth M; Zhong B; Lan X; Tian J; He Q; Li D; Sun J; Yang X; Lu S
Sci Rep; 2016 Feb; 6():21810. PubMed ID: 26911452
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
